Elevatus Welath Management’s AbbVie ABBV Stock Holding History

Elevatus Welath Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$844K	Buy	3,353 +1,155	+53%	+$248K	0.21%	96
2026 Q1	$478K	Sell	2,198 -1,178	-35%	-$261K	0.25%	73
2025 Q4	$771K	Buy	3,376 +43	+1%	+$9.79K	0.21%	75
2025 Q3	$772K	Buy	3,333 +433	+15%	+$88.2K	0.22%	60
2025 Q2	$538K	Buy	2,900 +790	+37%	+$147K	0.18%	62
2025 Q1	$442K	Sell	2,110 -450	-18%	-$87.5K	0.25%	57
2024 Q4	$455K	Buy	2,560 +1,175	+85%	+$216K	0.16%	62
2024 Q3	$274K	Sell	1,385 -9,391	-87%	-$1.75M	0.09%	73
2024 Q2	$1.85M	Buy	10,776 +9,087	+538%	+$1.51M	0.69%	42
2024 Q1	$307K	Sell	1,689 -666	-28%	-$115K	0.12%	70
2023 Q4	$365K	Buy	2,355 +918	+64%	+$134K	0.17%	62
2023 Q3	$214K	Buy	+1,437	New	+$211K	0.19%	63

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Elevatus Welath Management's ABBV Position: Q2 2026 in Review

Elevatus Welath Management increased its AbbVie (ABBV) stake by 53% in Q2 2026, buying an estimated $248K and bringing the position to 3,353 shares worth $844K. The position accounts for 0.21% of the portfolio, ranked #96.

Elevatus Welath Management first reported a position in ABBV in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.85M in Q2 2024. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Elevatus Welath Management held 3,353 shares of AbbVie worth $844K as of Q2 2026.
Elevatus Welath Management bought 1,155 AbbVie shares in Q2 2026, an estimated $248K.
AbbVie made up 0.21% of Elevatus Welath Management's portfolio in Q2 2026, its #96 holding.
Elevatus Welath Management first reported a position in AbbVie in Q3 2023 and has held it in 12 quarters since.
Elevatus Welath Management's AbbVie position peaked at $1.85M in Q2 2024.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Elevatus Welath Management's 13F filing for Q2 2026, filed 13 Aug 2026.